Plus Therapeutics (PSTV) announced the appointment of Eric Daniels as chief development officer, effective April 20. Daniels most recently served as chief development officer at Kiora Pharmaceuticals, where he oversaw the company’s full development portfolio, including clinical, preclinical, and CMC activities, and worked closely with executive leadership and Kiora’s board of directors to define and execute development strategy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Gains FDA Orphan Status for REYOBIQ
- Plus Therapeutics granted Orphan Drug Designation for Reyobiq
- Plus Therapeutics price target lowered to $12 from $37.50 at Maxim
- Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code
- Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation